Fibromyalgia Therapeutics – Global Strategic Business Report 2018-2022 – ResearchAndMarkets.com

The “Fibromyalgia
Therapeutics – Global Strategic Business Report” report has
been added to ResearchAndMarkets.com’s offering.

Annual estimates and forecasts are provided for the period 2015 through
2022. Also, a six-year historic analysis is provided for this market.
The report analyzes the Global market for Fibromyalgia Therapeutics in
US$ Million.

The report profiles 22 companies including many key and niche
players such as:

Key Topics Covered

1. INDUSTRY OVERVIEW

Fibromyalgia Syndrome: A Prelude

Fibromyalgia Therapeutics Market: A Nascent Sector

A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio

FDA Approved Fibromyalgia Drugs

IMC-1: A Revolutionary Combination Therapy

Daiichi Sankyo’s Mirogabalin Drug Improvises on Lyrica

Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine

Understanding Heightened Effect of Pain in Women Due to Fibromyalgia

Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses

Fibromyalgia Treatment through High-Pressure Oxygen Application

EU approves New Device to Treat Fibromyalgia and Migraine

2. AVAILABLE & PIPELINE FIBROMYALGIA DRUGS

AN OVERVIEW

Medications Used in the Fibromyalgia Treatment

Pain Relievers

Antidepressants

Anti-Seizure Drugs

Medication for Improving Sleep

Muscle Relaxants

Antipsychotics

A Glance at Available Fibromyalgia Drugs

Lyrica (pregabalin)

Cymbalta (duloxetine HCl)

Savella (milnacipran HCl)

Fibromyalgia Products in Pipeline

Mirogabalin

IMC-1

SWT06101

3. FIBROMYALGIA

THE DISEASE, SYMPTOMS, AND DIAGNOSIS

4. MANAGEMENT OF FIBROMYALGIA

Non-Pharmacological Treatment of Fibromyalgia

Nutritional Therapy

Exercise

Cognitive Behavior Therapy

Pharmacological Treatment Alternatives for Fibromyalgia

Antidepressants

Tricyclic Antidepressants (TCA)

Dopamine Agonists

Muscle Relaxants

Selective Serotonin-Norephinephrine Inhibitors (SNRIs)

Selective Serotonin Reuptake Inhibitors (SSRIs)

Drug Therapy for Fibromyalgia-Related Fatigue

Other Therapeutic Agents for Fibromyalgia Treatment

Conclusion

5. CLINICAL STUDIES & PRODUCT LAUNCHES/APPROVALS

Cannabis Science Introduces Fibromyalgia Pain Relief Medication

Soterix Medical Launches PainX tDCS Treatment in Canada

Synovation Medical Group to Conduct Study on NeuroMetrix’s Quell
Wearable Pain Relief Technology

FDA Grants Fast Track Designation to Innovative Med Concepts’ IMC-1

Soterix Medical’s PainX Treatment Receives CE Mark Approval

Tonix Pharmaceuticals Begins Phase 3 Trial of TNX-102 SL

Pfizer’s Lyrica Fails to Meet FDA Requirements in Post- Marketing Study

Premier Biomedical to Submit Application to FDA for Fibromyalgia Therapy

6. FOCUS ON SELECT GLOBAL PLAYERS

Allergan plc (Ireland)

Boehringer Ingelheim GmbH (Germany)

Daiichi Sankyo Company Limited (Japan)

Eli Lilly and Company (USA)

Innovative Med Concepts, Inc. (USA)

Pfizer, Inc. (USA)

Pierre Fabre Mdicament (France)

SWITCHBIOTECH LLC (USA)

Zynerba Pharmaceuticals, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 22 (including Divisions/Subsidiaries
23)

For more information about this report visit https://www.researchandmarkets.com/research/l2ckjn/fibromyalgia?w=4

Did you know that we also offer Custom Research? Visit our Custom
Research page to learn more and schedule a meeting with our Custom
Research Manager.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005785/en/

Leave a Comment